XEOMIN: payments to doctors
Payments that named XEOMIN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $13.9M
- Providers
- 23,097
- Transactions
- 100,607
- Average per transaction
- $138
The per-transaction average — $138 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 23,097 providers the average total is $601, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Merz North America, Inc. | $6,108,229 | 44.0% |
| MERZ North America, Inc. | $4,604,195 | 33.2% |
| Merz Pharmaceuticals, LLC | $3,160,522 | 22.8% |